The BCMA-targeting drugs Ide-cel (ROR = 13.00) and Cilta-cel (ROR = 168.90) were found to be associated with parkinsonism, which were not observed in CD19-targeting drugs. Here, TNFRSF17 is linked to Parkinson disease.